Harris S R, Garlick R K, Miller J J, Harney H N, Monroe P J
E.I.Du Pont de Nemours, Biotechnology Systems Division, Billerica, MA 01862.
J Recept Res. 1991;11(1-4):115-28. doi: 10.3109/10799899109066393.
The complement C5a receptor on U937 cells, a human histiocytic lymphoma cell line, stimulated with dibutyryl-cAMP have been stabilized for at least 3 months at a dilute, ready to use concentration. [125I]-Bolton Hunter labeled C5a, (recombinant, human) has been prepared by reverse phase HPLC to 2200 Ci/mmol. Using a filtration binding assay the Kd from receptor saturation analysis is 10-40 pM and there are 50,000-100,000 receptor sites per cell. These reagents have permitted the development of a reliable, reproducible and convenient drug screening assay, in kit format, for compounds acting at the C5a receptor.
用二丁酰环磷腺苷（dibutyryl-cAMP）刺激的人组织细胞淋巴瘤细胞系U937细胞上的补体C5a受体，已在稀释的即用浓度下稳定保存至少3个月。[125I]-博尔顿·亨特标记的C5a（重组人源）已通过反相高效液相色谱法制备至2200 Ci/mmol。使用过滤结合试验，受体饱和分析得出的解离常数（Kd）为10 - 40 pM，每个细胞有50,000 - 100,000个受体位点。这些试剂使得能够开发出一种可靠、可重复且方便的试剂盒形式的药物筛选试验，用于检测作用于C5a受体的化合物。
